Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 114

1.

Lymph node involvement and the surgical treatment of thymic epithelial and neuroendocrine carcinoma.

Cheufou DH, Valdivia D, Puhlvers S, Fels B, Weinreich G, Taube C, Theegarten D, Stuschke M, Schuler M, Hegedus B, Stamatis G, Aigner C.

Ann Thorac Surg. 2019 Feb 2. pii: S0003-4975(19)30132-8. doi: 10.1016/j.athoracsur.2019.01.006. [Epub ahead of print]

PMID:
30721691
2.

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma.

Laszlo V, Valko Z, Ozsvar J, Kovacs I, Garay T, Hoda MA, Klikovits T, Stockhammer P, Aigner C, Gröger M, Klepetko W, Berger W, Grusch M, Tovari J, Waizenegger IC, Dome B, Hegedus B.

J Mol Med (Berl). 2019 Feb;97(2):231-242. doi: 10.1007/s00109-018-1725-7. Epub 2018 Dec 11.

3.

New insights into the impact of primary lung adenocarcinoma location on metastatic sites and sequence: A multicenter cohort study.

Klikovits T, Lohinai Z, Fábián K, Gyulai M, Szilasi M, Varga J, Baranya E, Pipek O, Csabai I, Szállási Z, Tímár J, Hoda MA, Laszlo V, Hegedűs B, Renyi-Vamos F, Klepetko W, Ostoros G, Döme B, Moldvay J.

Lung Cancer. 2018 Dec;126:139-148. doi: 10.1016/j.lungcan.2018.11.004. Epub 2018 Nov 5.

PMID:
30527178
4.

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.

Kenessey I, Kramer Z, István L, Cserepes MT, Garay T, Hegedűs B, Dobos J, Tímár J, Tóvári J.

Melanoma Res. 2018 Dec;28(6):536-546. doi: 10.1097/CMR.0000000000000488.

PMID:
30124539
5.

DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells.

Laengle J, Stift J, Bilecz A, Wolf B, Beer A, Hegedus B, Stremitzer S, Starlinger P, Tamandl D, Pils D, Bergmann M.

Theranostics. 2018 May 10;8(12):3198-3213. doi: 10.7150/thno.24699. eCollection 2018.

6.

The role of lipid signaling in the progression of malignant melanoma.

Tímár J, Hegedüs B, Rásó E.

Cancer Metastasis Rev. 2018 Sep;37(2-3):245-255. doi: 10.1007/s10555-018-9729-x.

PMID:
29808460
7.

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

Molnár E, Rittler D, Baranyi M, Grusch M, Berger W, Döme B, Tóvári J, Aigner C, Tímár J, Garay T, Hegedűs B.

BMC Cancer. 2018 May 8;18(1):542. doi: 10.1186/s12885-018-4455-x.

8.

Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo.

Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirok A, Garay T, Stiglbauer A, Helbich TH, Gröger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B.

Clin Cancer Res. 2018 Aug 1;24(15):3729-3740. doi: 10.1158/1078-0432.CCR-17-1507. Epub 2018 May 3.

PMID:
29724868
9.

FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.

Schelch K, Wagner C, Hager S, Pirker C, Siess K, Lang E, Lin R, Kirschner MB, Mohr T, Brcic L, Marian B, Holzmann K, Grasl-Kraupp B, Krupitza G, Laszlo V, Klikovits T, Dome B, Hegedus B, Garay T, Reid G, van Zandwijk N, Klepetko W, Berger W, Grusch M, Hoda MA.

Carcinogenesis. 2018 Apr 5;39(4):534-545. doi: 10.1093/carcin/bgy018.

PMID:
29635378
10.

Reshaping a multimode laser beam into a constructed Gaussian beam for generating a thin light sheet.

Saghafi S, Haghi-Danaloo N, Becker K, Sabdyusheva I, Foroughipour M, Hahn C, Pende M, Wanis M, Bergmann M, Stift J, Hegedus B, Dome B, Dodt HU.

J Biophotonics. 2018 Jun;11(6):e201700213. doi: 10.1002/jbio.201700213. Epub 2018 Mar 24.

PMID:
29457696
11.

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma.

Klikovits T, Stockhammer P, Laszlo V, Dong Y, Hoda MA, Ghanim B, Opitz I, Frauenfelder T, Nguyen-Kim TDL, Weder W, Berger W, Grusch M, Aigner C, Klepetko W, Dome B, Renyi-Vamos F, Oehler R, Hegedus B.

Sci Rep. 2017 Nov 28;7(1):16456. doi: 10.1038/s41598-017-16551-7.

12.

FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo.

Ghassemi S, Vejdovszky K, Sahin E, Ratzinger L, Schelch K, Mohr T, Peter-Vörösmarty B, Brankovic J, Lackner A, Leopoldi A, Meindl D, Pirker C, Hegedus B, Marian B, Holzmann K, Grasl-Kraupp B, Heffeter P, Berger W, Grusch M.

Oncotarget. 2017 Sep 23;8(50):87750-87762. doi: 10.18632/oncotarget.21184. eCollection 2017 Oct 20.

13.

The role of Allee effect in modelling post resection recurrence of glioblastoma.

Neufeld Z, von Witt W, Lakatos D, Wang J, Hegedus B, Czirok A.

PLoS Comput Biol. 2017 Nov 17;13(11):e1005818. doi: 10.1371/journal.pcbi.1005818. eCollection 2017 Nov.

14.

Starvation- and xenobiotic-related transcriptomic responses of the sulfanilic acid-degrading bacterium, Novosphingobium resinovorum SA1.

Hegedüs B, Kós PB, Bende G, Bounedjoum N, Maróti G, Laczi K, Szuhaj M, Perei K, Rákhely G.

Appl Microbiol Biotechnol. 2018 Jan;102(1):305-318. doi: 10.1007/s00253-017-8553-5. Epub 2017 Oct 19.

PMID:
29051988
15.

Targeting an Oncolytic Influenza A Virus to Tumor Tissue by Elastase.

Kuznetsova I, Arnold T, Aschacher T, Schwager C, Hegedus B, Garay T, Stukova M, Pisareva M, Pleschka S, Bergmann M, Egorov A.

Mol Ther Oncolytics. 2017 Sep 8;7:37-44. doi: 10.1016/j.omto.2017.09.002. eCollection 2017 Dec 15.

16.

The Potential Role of Thermography in Determining the Efficacy of Stroke Rehabilitation.

Hegedűs B.

J Stroke Cerebrovasc Dis. 2018 Feb;27(2):309-314. doi: 10.1016/j.jstrokecerebrovasdis.2017.08.045. Epub 2017 Oct 10.

PMID:
29030045
17.

Intrathoracic solitary fibrous tumor - an international multicenter study on clinical outcome and novel circulating biomarkers.

Ghanim B, Hess S, Bertoglio P, Celik A, Bas A, Oberndorfer F, Melfi F, Mussi A, Klepetko W, Pirker C, Berger W, Harmati I, Farkas A, Jan Ankersmit H, Dome B, Fillinger J, Aigner C, Hegedus B, Renyi-Vamos F, Lang G.

Sci Rep. 2017 Oct 2;7(1):12557. doi: 10.1038/s41598-017-12914-2.

18.

Same-day Routine Chest-X Ray After Thoracic Surgery is Not Necessary!

Nagy P, Antony C, Hegedüs B, Kampe S, Ploenes T, Aigner C, Welter S.

Zentralbl Chir. 2018 Feb;143(1):96-101. doi: 10.1055/s-0043-117174. Epub 2017 Sep 13.

PMID:
28905345
19.

BARD1 serum autoantibodies for the detection of lung cancer.

Pilyugin M, Descloux P, André PA, Laszlo V, Dome B, Hegedus B, Sardy S, Janes S, Bianco A, Laurent GJ, Irminger-Finger I.

PLoS One. 2017 Aug 7;12(8):e0182356. doi: 10.1371/journal.pone.0182356. eCollection 2017.

20.

Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca2+ Pump PMCA4b and Inhibits the Migration of Melanoma Cells Independent of ERK.

Hegedüs L, Padányi R, Molnár J, Pászty K, Varga K, Kenessey I, Sárközy E, Wolf M, Grusch M, Hegyi Z, Homolya L, Aigner C, Garay T, Hegedüs B, Tímár J, Kállay E, Enyedi Á.

Front Oncol. 2017 May 24;7:95. doi: 10.3389/fonc.2017.00095. eCollection 2017.

21.

Cell type-dependent HIF1 α-mediated effects of hypoxia on proliferation, migration and metastatic potential of human tumor cells.

Tátrai E, Bartal A, Gacs A, Paku S, Kenessey I, Garay T, Hegedűs B, Molnár E, Cserepes MT, Hegedűs Z, Kucsma N, Szakács G, Tóvári J.

Oncotarget. 2017 Jul 4;8(27):44498-44510. doi: 10.18632/oncotarget.17806.

22.

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.

Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, Fabian K, Kovalszky I, Kenessey I, Aigner C, Renyi-Vamos F, Klepetko W, Dome B, Hegedus B.

Sci Rep. 2017 Jan 4;7:39721. doi: 10.1038/srep39721.

23.

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors.

Torok S, Rezeli M, Kelemen O, Vegvari A, Watanabe K, Sugihara Y, Tisza A, Marton T, Kovacs I, Tovari J, Laszlo V, Helbich TH, Hegedus B, Klikovits T, Hoda MA, Klepetko W, Paku S, Marko-Varga G, Dome B.

Theranostics. 2017 Jan 1;7(2):400-412. doi: 10.7150/thno.16767. eCollection 2017.

24.

A comparison of sample preparation strategies for biological tissues and subsequent trace element analysis using LA-ICP-MS.

Bonta M, Török S, Hegedus B, Döme B, Limbeck A.

Anal Bioanal Chem. 2017 Mar;409(7):1805-1814. doi: 10.1007/s00216-016-0124-6. Epub 2016 Dec 14.

25.

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.

26.

Complete genome sequence of Novosphingobium resinovorum SA1, a versatile xenobiotic-degrading bacterium capable of utilizing sulfanilic acid.

Hegedűs B, Kós PB, Bálint B, Maróti G, Gan HM, Perei K, Rákhely G.

J Biotechnol. 2017 Jan 10;241:76-80. doi: 10.1016/j.jbiotec.2016.11.013. Epub 2016 Nov 13.

PMID:
27851894
27.

The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells.

Hegedũs L, Garay T, Molnár E, Varga K, Bilecz Á, Török S, Padányi R, Pászty K, Wolf M, Grusch M, Kállay E, Döme B, Berger W, Hegedũs B, Enyedi A.

Int J Cancer. 2017 Jun 15;140(12):2758-2770. doi: 10.1002/ijc.30503. Epub 2016 Nov 17.

28.

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.

Kenessey I, Kói K, Horváth O, Cserepes M, Molnár D, Izsák V, Dobos J, Hegedűs B, Tóvári J, Tímár J.

Oncotarget. 2016 Nov 29;7(48):79503-79514. doi: 10.18632/oncotarget.12806.

29.

Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo.

Hock K, Laengle J, Kuznetsova I, Egorov A, Hegedus B, Dome B, Wekerle T, Sachet M, Bergmann M.

Surgery. 2017 Mar;161(3):735-746. doi: 10.1016/j.surg.2016.08.045. Epub 2016 Oct 21.

PMID:
27776794
30.

Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.

Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W.

Mol Cancer Ther. 2016 Oct;15(10):2357-2369. Epub 2016 Aug 10.

31.

Divergent Reactivity of Thioalkynes in Lewis Acid Catalyzed Annulations with Donor-Acceptor Cyclopropanes.

Racine S, Hegedüs B, Scopelliti R, Waser J.

Chemistry. 2016 Aug 16;22(34):11997-2001. doi: 10.1002/chem.201602755. Epub 2016 Jul 19.

PMID:
27431096
32.

[Interdisciplinary rehabilitation in patients with ankylosing spondylitis].

Hegedűs B, Varga J, Somfay A.

Orv Hetil. 2016 Jul;157(28):1126-32. doi: 10.1556/650.2016.30472. Hungarian.

PMID:
27397425
33.

Region Specific Differences of Claudin-5 Expression in Pediatric Intracranial Ependymomas: Potential Prognostic Role in Supratentorial Cases.

Virág J, Haberler C, Baksa G, Piurkó V, Hegedüs Z, Reiniger L, Bálint K, Chocholous M, Kiss A, Lotz G, Glasz T, Schaff Z, Garami M, Hegedűs B.

Pathol Oncol Res. 2017 Apr;23(2):245-252. doi: 10.1007/s12253-016-0084-3. Epub 2016 Jul 9.

34.

Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.

Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, Stockhammer P, Ozsvar J, Jakopovic M, Samarzija M, Brcic L, Bendek M, Szirtes I, Reid G, Kirschner MB, Kao SC, Opitz I, Weder W, Frauenfelder T, Nguyen-Kim TD, Aigner C, Klepetko W, van Zandwijk N, Berger W, Dome B, Grusch M, Hegedus B.

Eur J Cancer. 2016 Aug;63:64-73. doi: 10.1016/j.ejca.2016.04.018. Epub 2016 Jun 8.

PMID:
27288871
35.

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma.

Hoda MA, Rozsas A, Lang E, Klikovits T, Lohinai Z, Torok S, Berta J, Bendek M, Berger W, Hegedus B, Klepetko W, Renyi-Vamos F, Grusch M, Dome B, Laszlo V.

Oncotarget. 2016 Mar 22;7(12):13388-99. doi: 10.18632/oncotarget.7796.

36.

RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.

Szabo A, Fekete T, Koncz G, Kumar BV, Pazmandi K, Foldvari Z, Hegedus B, Garay T, Bacsi A, Rajnavolgyi E, Lanyi A.

Cell Signal. 2016 May;28(5):335-347. doi: 10.1016/j.cellsig.2016.01.012. Epub 2016 Jan 29.

PMID:
26829212
37.

Application of dried-droplets deposited on pre-cut filter paper disks for quantitative LA-ICP-MS imaging of biologically relevant minor and trace elements in tissue samples.

Bonta M, Hegedus B, Limbeck A.

Anal Chim Acta. 2016 Feb 18;908:54-62. doi: 10.1016/j.aca.2015.12.048. Epub 2016 Jan 11.

PMID:
26826687
38.

Differences in the Epidemiology of Rare EGFR Mutations in Different Populations.

Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2016 Jan;11(1):e19-20. doi: 10.1016/j.jtho.2015.09.003. No abstract available.

39.

From Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC).

Lohinai Z, Dome P, Szilagyi Z, Ostoros G, Moldvay J, Hegedus B, Dome B, Weiss GJ.

PLoS One. 2016 Jan 6;11(1):e0144797. doi: 10.1371/journal.pone.0144797. eCollection 2016.

40.

[Excerpts from the collaborative lung cancer research program of Semmelweis University, the National Institute of Oncology and Korányi Institute of TB and Pulmonology (2010-2015)].

Hegedûs B, Moldvay J, Berta J, Lohinai Z, Rózsás A, Cserepes MT, Fábián K, Ostoros G, Tóvári J, Rényi-Vámos F, Tímár J, Döme B.

Magy Onkol. 2015 Dec;59(4):282-5. Epub 2015 Nov 21. Hungarian.

41.

[Melanoma research in Hungary: promising results in a previously orphan tumor].

Balázs M, Vízkeleti L, Ecsedi S, Ádány R, Rásó E, Hegedûs B, Ladányi A, Tóvári J, Tímár J.

Magy Onkol. 2015 Dec;59(4):275-81. Epub 2015 Oct 25. Hungarian.

42.

Metabolic responses of Rhodococcus erythropolis PR4 grown on diesel oil and various hydrocarbons.

Laczi K, Kis Á, Horváth B, Maróti G, Hegedüs B, Perei K, Rákhely G.

Appl Microbiol Biotechnol. 2015 Nov;99(22):9745-59. doi: 10.1007/s00253-015-6936-z. Epub 2015 Sep 8.

PMID:
26346267
43.

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Kirschner MB, Pulford E, Hoda MA, Rozsas A, Griggs K, Cheng YY, Edelman JJ, Kao SC, Hyland R, Dong Y, László V, Klikovits T, Vallely MP, Grusch M, Hegedus B, Dome B, Klepetko W, van Zandwijk N, Klebe S, Reid G.

Br J Cancer. 2015 Sep 15;113(6):963-9. doi: 10.1038/bjc.2015.286. Epub 2015 Aug 11.

44.

Reply to Rare Versus Artifactual EGFR Mutations.

Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 Aug;10(8):e80-1. doi: 10.1097/JTO.0000000000000591. No abstract available.

45.

Epigenetic down-regulation of integrin α7 increases migratory potential and confers poor prognosis in malignant pleural mesothelioma.

Laszlo V, Hoda MA, Garay T, Pirker C, Ghanim B, Klikovits T, Dong YW, Rozsas A, Kenessey I, Szirtes I, Grusch M, Jakopovic M, Samarzija M, Brcic L, Kern I, Rozman A, Popper H, Zöchbauer-Müller S, Heller G, Altenberger C, Ziegler B, Klepetko W, Berger W, Dome B, Hegedus B.

J Pathol. 2015 Oct;237(2):203-14. doi: 10.1002/path.4567. Epub 2015 Jul 14.

PMID:
26011651
46.

Cancer cell-autonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis.

von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J, Legler K, Annewanter F, Campbell AD, Taraborrelli L, Grosse-Wilde A, Coy JF, El-Bahrawy MA, Bergmann F, Koschny R, Werner J, Ganten TM, Schweiger T, Hoetzenecker K, Kenessey I, Hegedüs B, Bergmann M, Hauser C, Egberts JH, Becker T, Röcken C, Kalthoff H, Trauzold A, Anderson KI, Sansom OJ, Walczak H.

Cancer Cell. 2015 Apr 13;27(4):561-73. doi: 10.1016/j.ccell.2015.02.014. Epub 2015 Apr 2.

47.

Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases.

Schweiger T, Nikolowsky C, Starlinger P, Traxler D, Zimmermann M, Birner P, Hegedüs B, Dome B, Bergmann M, Mildner M, Klepetko W, Hoetzenecker K, Ankersmit HJ.

PLoS One. 2015 Mar 20;10(3):e0120724. doi: 10.1371/journal.pone.0120724. eCollection 2015.

48.

Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.

Garay T, Molnár E, Juhász É, László V, Barbai T, Dobos J, Schelch K, Pirker C, Grusch M, Berger W, Tímár J, Hegedűs B.

Pathol Oncol Res. 2015 Sep;21(4):957-68. doi: 10.1007/s12253-015-9916-9. Epub 2015 Mar 9.

PMID:
25749811
49.

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma.

Lohinai Z, Hoda MA, Fabian K, Ostoros G, Raso E, Barbai T, Timar J, Kovalszky I, Cserepes M, Rozsas A, Laszlo V, Grusch M, Berger W, Klepetko W, Moldvay J, Dome B, Hegedus B.

J Thorac Oncol. 2015 May;10(5):738-46. doi: 10.1097/JTO.0000000000000492.

50.

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.

Garay T, Kenessey I, Molnár E, Juhász É, Réti A, László V, Rózsás A, Dobos J, Döme B, Berger W, Klepetko W, Tóvári J, Tímár J, Hegedűs B.

PLoS One. 2015 Feb 3;10(2):e0117021. doi: 10.1371/journal.pone.0117021. eCollection 2015.

Supplemental Content

Loading ...
Support Center